Medicare & MedicaidBack to stories →
← Back to stories
Billing & paymentNew in this edition

Noridian posts MolDX billing-article revisions for October 1

Noridian’s September 24 MolDX notices announce October diagnosis-code changes and separately dated revisions. Article maintenance does not itself establish coverage for every listed test.

Illustrative artwork. Fictional scene, not a photograph of the people or events in this story.

What happened

Noridian posted five relevant JE MolDX article revisions on September 24. The notices cover myeloid next-generation sequencing A57891 R14, hereditary transthyretin amyloidosis A59872 R3, heritable thoracic aortic disease A59868 R3, cardiovascular-risk biomarkers A57037 R9 and metabolic steatotic liver disease/steatohepatitis biomarkers A60217 R1. Their October 1 changes include diagnosis-code additions or replacements, such as M04.3 for the myeloid article, Q87.A for the aortic article and K74.0A for the liver article. At the September 26 cutoff, those October 1 portions are still ahead and need comparison with actual services and diagnosis documentation.

The notices do not give every change the same start date. The myeloid notice also adds genomic sequencing code entries and a warning that inclusion does not imply coverage, with that portion effective May 17, 2020. The amyloidosis notice includes cardiomyopathy code additions effective September 25, 2025 alongside October 2026 replacements and registry wording. Article maintenance therefore requires version-specific comparison rather than assuming every listed code creates coverage or a new October-only benefit.

Scope and timing

Authority status
Final
Applicability
Directly applicable
Audience
Health systems, Provider networks
Jurisdiction
Federal, California
Affected functions
Clinical Operations, Revenue Cycle, Coding, Compliance
Responsible owner
Revenue Cycle
Recorded date
2026-10-01
Date type
implementation

Why it matters

Laboratory edits must apply the correct revision and effective date while preserving the distinction between coding inclusion, evaluated tests and clinical coverage.

Implementation playbook

  1. Internal target: Identify every revised MolDX article tied to tests currently ordered or billed. Clinical Operations · Due 2026-09-28
  2. Internal target: Update applicable coding, documentation, and claim edits. Coding · Due 2026-09-30
  3. Internal target: Verify October 1 production readiness. Revenue Cycle · Due 2026-10-01

Sources

Complete edition and supplemental material

This finding in the complete approved report →

Regulatory horizons, CIA trends and implementation trackers remain in the full report.

Read the entire Medicare & Medicaid report →

← Return to stories

Privacy preferences

Where enabled for this site, Cloudflare Web Analytics can send page-use and performance measurements to Cloudflare. This panel provides information and does not turn analytics on or off.

This panel stores no tracking choice and does not change your tool saves, screening, resets, reports or exports. Other sites have separate settings.

Read Privacy & Cookies